doi: 10.1161/CIRCULATIONAHA.105.545616
(Circulation. 2005;112:578-586.)
© 2005 American Heart Association, Inc.
Vascular Medicine |
Inhibition of Atherogenesis in BLT1-Deficient Mice Reveals a Role for LTB4 and BLT1 in Smooth Muscle Cell Recruitment
From the Center for Immunology and Inflammatory Diseases (E.A.H., E.L., A.M.T., S.S., A.D.L., R.E.G.), Cardiovascular Research Center (E.A.H., E.L., J.D.R., J.Q.C., P.H., R.E.G.), Massachusetts General Hospital, Charlestown, and Harvard Medical School, Boston, Mass; Lipid Metabolism Unit and Endocrine Division (S.L.K., M.W.F., K.J.M.), Massachusetts General Hospital and Harvard Medical School, Boston, Mass; Vascular Medicine and Atherosclerosis Unit (P.L., E.R.A.), Cardiovascular Division, Brigham and Women’s Hospital, and Harvard Medical School, Boston, Mass; and Donald W. Reynolds Cardiovascular Clinical Research Center on Atherosclerosis at Harvard Medical School (P.L., E.R.A., R.E.G.), Boston, Mass.
Correspondence to Dr R.E. Gerszten, Cardiology Division and Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital East-8307, 149 13th St, Charlestown, MA 02129. E-mail rgerszten{at}partners.org
Received March 2, 2005; revision received April 7, 2005; accepted April 12, 2005.
 |
Abstract |
|---|
 Top Abstract IntroductionMethodsResultsDiscussionReferences |
|---|
Background— It is known that 5-lipoxygenase and its product, leukotriene B4 (LTB4), are highly expressed in several human pathologies, including atherosclerotic plaque. LTB4 signals primarily through its high-affinity G protein-coupled receptor BLT1, which is expressed on specific leukocyte subsets. BLT1 receptor expression and function on other atheroma-associated cell types is unknown.
Methods and Results— To directly assess the role of the LTB4-BLT1 pathway in atherogenesis, we bred BLT1–/– mice into the atherosclerosis-susceptible apoE–/– strain. Compound-deficient apoE–/–/Blt1–/– mice fed a Western-type diet had a marked reduction in plaque formation compared with apoE–/– controls. Immunohistochemical analysis of atherosclerotic lesions in compound-deficient mice revealed a striking decrease in smooth muscle cells (SMCs) and significant decreases in macrophages and T cells. We report here novel evidence of the expression and function of BLT1 on vascular SMCs. LTB4 triggered SMC chemotaxis, which was pertussis toxin sensitive in Blt1+/+ SMCs and absent in Blt1–/– cells, suggesting that BLT1 was the dominant receptor mediating effector functions through a G protein-coupled signaling pathway. Furthermore, BLT1 colocalized with SMCs in human atherosclerotic lesions.
Conclusions— These new findings extend the role of inducible BLT1 to nonleukocyte populations and suggest an important target for intervention to modulate the response to vascular injury.
Key Words: atherosclerosis • inflammation • leukotrienes • muscle, smooth
|
Introduction |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Leukotriene B4 (LTB4) is an eicosanoid lipid derivative of the arachadonic acid signaling pathway generated by 5-lipoxygenase (5-LO) and leukotriene A4 hydrolase. LTB4 is a proinflammatory mediator that activates multiple leukocyte subsets, leading to cell recruitment, production of reactive oxygen species, and induction of gene expression.1–8 LTB4 signals primarily through its high-affinity G protein-coupled receptor BLT1, which is highly expressed in specific subsets of circulating peripheral blood leukocytes and present in much lower amounts in spleen, thymus, bone marrow, lymph nodes, heart, skeletal muscle, brain, and liver. A low-affinity receptor, BLT2,9–12 is also ubiquitously expressed at low levels in many human tissues.12,13 Interestingly, recent studies have demonstrated marked induction of BLT1 expression by proinflammatory cytokines such as those that govern the transition of naïve to effector T cells.14 Such studies raise the possibility that BLT1 expression may be increased in other cell types during inflammatory processes.
A mounting body of correlative evidence has linked LTB4 to several chronic inflammatory conditions, including atherosclerosis. We know that 5-LO and its derivatives are highly expressed within human carotid, aortic, and coronary artery plaques.15,16 Genetic studies have associated particular variants of 5-LO and its accessory protein, 5-LO activating protein, with stroke and myocardial infarction in humans.17,18 Two recent murine studies suggest a causal role for the LTB4-BLT1 axis in atherosclerotic lesion formation. Treatment of the atherosclerosis-susceptible Ldlr–/– and apoE–/– mice with a small-molecule BLT1 antagonist reduced plaque burden,19 a finding that was confirmed more recently in apoE–/–/Blt1–/– compound-deficient mice.20 Both groups observed diminished macrophage accumulation and suggested that it was the primary contribution of LTB4 and BLT1 to atherogenesis.
Atherosclerotic lesions are marked by the recruitment of not only macrophages but also other leukocytes such as memory T cells, as well as nonleukocytes, including vascular smooth muscle cells (SMCs). In light of recent data demonstrating functionally significant cytokine-induced expression of BLT1 in previously unanticipated leukocyte subsets,14 we generated apoE–/–/Blt1–/– compound-deficient mice to evaluate the pleiotropic effects of the LTB4-BLT1 pathway on the multiple cell types involved in atherosclerotic lesion formation. We report here the expression and function of BLT1 on SMCs in vitro and in vivo. These findings extend the role of inducible BLT1 to nonleukocyte populations and suggest an important target for intervention to modulate the response to vascular injury.
|
Methods |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Animals
Blt1–/– mice1 were backcrossed 10 times into a C57/BL6J background and subsequently bred with apoE–/– mice21 (Jackson Laboratory). Intercrosses of resulting apoE–/–/Blt1+/– mice yielded offspring that entered the study. Genotyping for BLT11 and apoE22 was performed by PCR. The mice were fed a high-fat Western-type diet (0.15% cholesterol, 21% fat; Harlan Teklad TD88137) beginning at 4 weeks of age for 6 or 12 weeks.
Blood and Plasma Analysis
We obtained 0.5 to 1.0 mL of blood from experimental mice by right ventricular puncture on death. A small aliquot of blood was analyzed for complete blood count (Drew Scientific); the remainder was used for analysis of total cholesterol and triglyceride levels (Roche Diagnostics) in the MGH Clinical Laboratories.
En Face Lesion Analysis
Aortas were dissected from mice of the indicated age, stained with oil red O (ORO), and analyzed as previously described.22–24 Images were obtained with a Nikon Coolpix camera attached to an inverted microscope. The percentage of ORO-stained lesion area was determined by Image Pro Plus image analysis software. Lesion analysis was conducted by a single observer blinded to the genotype of the mice.
Murine Aortic Root Lesion Analysis and Immunohistochemistry
The heart and aortic root were dissected and removed as described above and embedded in OCT. Serial sections were cut through the aorta at the level of the aortic valve leaflets, and every third section (5-µm intervals) through the aortic sinus (400-µm total length) was stained with ORO and hematoxylin.24 Immunohistochemistry was performed with antibodies to identify SMCs (
-actin, 1:50; DAKO), macrophages (M
) (F4/80, 1:25; Serotec), and T cells (CD4, 1:50; BD Biosciences) detected with either DAKO ARK peroxidase (DakoCytomation) or goat anti-rat HRP-conjugated IgG (1:50; BD Biosciences) as indicated. Negative controls were prepared by substitution with an isotype control antibody. Stained sections were digitally captured, and immunohistochemistry was quantified with IP Laboratory image analysis software (Scanalytics). Threshold color analysis by a single observer determined the plaque area and the percentage of plaque that stained for a particular antigen using standardized settings for all genotypes.
Immunohistochemistry of Human Atherosclerotic Lesions
Surgical specimens of human carotid atheroma were obtained using protocols approved by the Human Investigation Review Board at the Brigham and Women’s Hospital. Serial cryostat sections (5 µm) were cut, air dried onto microscope slides (Fisher Scientific Co), and fixed in acetone at –20°C for 5 minutes. Sections preincubated with PBS containing 0.3% hydrogen peroxide were then incubated for 90 minutes with primary or isotype-matched control antibody and diluted in PBS supplemented with 5% appropriate serum. After washing 3 times in PBS, sections were incubated with the respective biotinylated secondary antibody (for 45 minutes; Vector Laboratories), followed by avidin-biotin-peroxidase complex (VECTASTAIN ABC kit; Vector Laboratories). Immunostaining was viewed using 3-amino-9-ethyl carbazole (Vector Laboratories) according to the recommendations provided by the supplier. Cell types were characterized using the following cell-specific antibodies: anti-muscle actin mAb for SMCs (Enzo Diagnostics), anti-CD31 mAb for endothelial cells (DAKO Corp), and anti-CD68 mAb for M (DAKO Corp).
Murine Vascular SMC Isolation
Murine aortas were dissected, cut into 
1 mm2 segments, and then placed as explants in T25 flasks containing 1 mL RPMI with 20% FBS (2 to 3 aortas per flask).25 Flasks were incubated with 3 to 4 mL RPMI with 20% FBS once the SMC outgrowth had become >50% confluent. Staining with FITC-labeled anti-mouse smooth muscle -actin (1:50, DAKO) confirmed >99% SMC purity (not shown).
RNA Isolation and Quantitative PCR
Total RNA was isolated from either cultured SMCs or aortas from mice perfused with RNA Later (Ambion) using Trizol reagent (Invitrogen) and RNeasy columns (Qiagen).24,26 Briefly, after DNaseI digestion, 2 µg RNA from each sample was reverse transcribed using Taqman reverse-transcription reagents, including oligo (dT)15, random hexamers, and Multiscribe reverse transcriptase (Applied Biosystems). Quantitative (Q) RTPCR reactions were conducted with the Multiplex QPCR system as described.26 Amplification plots were analyzed with MX4000 software, version 3.0. Gene expression was normalized to GAPDH as an internal control.
LTB4 Signaling Studies and Western Blotting
After 24 hours of cytokine activation (tumor necrosis factor [TNF]- [20 ng/mL] and interferon [IFN]-
[1000U/mL]), SMCs were stimulated with either vehicle control or 100 nmol/L LTB4 in RPMI with 1% FBS for 5, 30, or 60 minutes. Reactions were stopped with ice cold 1x PBS without Ca2+ and Mg2+, and Western analysis of cell lysates was performed using the indicated antibodies as previously described.27,28 Rabbit anti-mouse phospho-focal adhesion kinase (FAK) and mouse anti-phospho-ERK 1/2 antibodies were obtained from Cell Signaling Technologies, Inc. Rabbit anti-mouse total FAK and total ERK 1/2 antibodies were purchased from Transduction Laboratories.
Vascular SMC Migration Assays
Murine aortic SMCs were activated with TNF- (20 ng/mL) and INF- (100 U/mL) for 24 hours in RPMI with 1% FBS. Once resuspended, 20 000 cells were added to the top wells of Costar Transwell modified Boyden chambers (6.5-mm-diameter tissue culture-treated polycarbonate membranes containing 8-µm pores). LTB4 was added to the top or bottom wells as indicated. For inhibitor studies, SMCs were pretreated with the BLT1 receptor antagonist CP-105,696 (Pfizer; 10 µmol/L, 30 minutes, 37°C), pertussis toxin (250 ng/mL, 1 hour, 37°C), or vehicle control. After incubation of the chemotaxis chambers at 37°C for 6 hours, membranes were fixed in methanol and stained with hematoxylin and eosin. Cells adherent to the bottom of the membranes were counted by phase contrast microscopy (x100 magnification).
Vascular SMC Proliferation Studies
Murine SMCs grown on 24-well plates underwent growth arrest for 3 days in 1% FBS, followed by stimulation with LTB4 (100 nmol/L, replaced daily), 20% FBS, or both during days 4 to 7. The relative cell numbers were subsequently determined using a fluorescent nucleic acid probe and quantitative epifluorescence29 (Cyquant).
Flow Cytometry
Human coronary artery SMCs used for flow cytometry experiments were a generous gift from Dr Mukesh Jain (Brigham & Women’s Hospital). Cells were either left untreated or activated with TNF- (20 ng/mL) and IFN- (1000 U/mL) for 48 hours as indicated. Adherent cells were placed in suspension as previously described,30 incubated with mouse anti-human FITC-labeled BLT1 antibody or mouse anti-human FITC-labeled IgG2a isotype control (both from Serotec), and then fixed in 1x PBS/2% paraformaldehyde. Samples were analyzed with a Becton-Dickinson FACS and CellQuest software.
Statistical Analysis
The null hypothesis for the variables measured in the 2 groups of animals or cell culture conditions was initially tested by Student t tests. If the data did not fit the constraints of a parametric test, they were analyzed by 1-way ANOVA. A value of P<0.05 was considered significant. All data are presented as mean±SEM or SD as indicated.
|
Results |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
To directly assess the role of BLT1 in atherogenesis, we backcrossed Blt1–/– mice 10 times onto a C57BLJ/6 background and then bred them to apoE–/– mice to generate compound-deficient apoE–/–/Blt1–/– and control apoE–/–/Blt1+/+ mice. Mice were placed on a high-fat, high-cholesterol Western diet for 6 or 12 weeks. There were no significant differences in total cholesterol or triglyceride levels between the 2 groups (the Table). Circulating white blood cell counts were also comparable, thus excluding any obvious confounding variables.
|
Lesion area was first quantified in aortas pinned out and stained with ORO. There was a striking reduction in aortic plaque burden at 6 weeks in the compound-deficient apoE–/–/Blt1–/– mice compared with the apoE–/– animals (1.72% versus 3.82% of total aortic area; 55% reduction; P=0.00003; Figure 1A and 1B). These findings were concordant across the aortic arch (53% reduction; P=0.00004), thoracic aorta (51.0% reduction; P=0.005), and abdominal aorta (72.4% reduction; P=0.001; Figure 1C). We observed decreased lesion formation in both male (52.9% reduction; P=0.008) and female (56.7% reduction; P=0.001; Figure 1D) mice without significant intergender differences (P=NS). En face analysis revealed a trend toward lesion reduction at the 12-week time point as well (Figure 1E).
|
We performed cross-sectional analysis of aortic roots in parallel with the en face studies. After 6 weeks on the Western-type diet, the average cross-sectional lesion area for apoE–/–/Blt1–/– mice was 214.7 µm2 as opposed to 480.3 µm2 for the apoE–/– controls (P=0.006; Figure 2A and 2b), concordant with the quantitative analysis of total aortic area involvement by surface lipid staining. A consistent decrease in aortic sinus lesion area was observed in the apoE–/–/Blt1–/– mice after 12 weeks on the Western-style diet, indicating that loss of BLT1 continues to affect lesion development in older mice (Figure 2C) (n=8 for each genotype; P=0.008).
|
Next, we performed immunohistochemical analysis to further delineate the effects of BLT1 on lesion formation (Figure 3A through 3C). Analyses were performed on the mice fed a Western-style diet for 6 weeks and were normalized to lesion area in light of the significant differences in plaque size between the 2 groups as noted above. Intimal area was decreased in cross sections of aortic root lesions from apoE–/–/Blt1–/– mice. There was a significant decrease in both monocyte (39.2% reduction; n=6; P=0.01) and T-cell (30.6%; n=6; P=0.03) accumulation in the plaques of the double-knockout mice compared with apoE–/– controls. The most unanticipated finding, however, was a striking inhibition (42.6% reduction; n=6; P=0.0000017) of SMC accumulation in the apoE–/–/Blt1–/– mice (Figure 3C). Staining for -actin was reduced both in the media and in the fibromuscular caps overlying the lesions. These findings were confirmed by a concordant 2-fold decrease in -actin mRNA in the aortic lesions as assessed by QPCR (Figure 3D).
|
The markedly diminished number of SMCs in the vessel wall of apoE–/–/Blt1–/– mice suggested that BLT1 may play a direct role in SMC recruitment and/or proliferation. We next assessed BLT1 expression in isolated murine aortic SMCs by PCR. Although resting SMCs showed no evidence of BLT1 expression, activation with TNF- and/or IFN- markedly enhanced expression over 24 hours (Figure 4A). QPCR confirmed a >25-fold increase in BLT1 expression in the TNF– and INF-–stimulated SMCs. (Figure 4B). Using a recently generated anti-human BLT1 mAb,31 we then examined surface expression of the protein on human coronary artery SMCs. Flow cytometry studies revealed low baseline staining, but >50% of SMCs expressed BLT1 after cytokine activation (Figure 4C). BLT1 expression was 8-fold higher than BLT2 expression, which was assessed by QPCR only because no antibody exists for this receptor (not shown).
|
To assess the potential functional effects of LTB4 on vascular SMCs, we performed migration assays in modified Boyden chambers. We observed robust, bell-shaped chemotaxis to LTB4 with a concentration-dependent response curve similar to recently published findings in activated T cells14 (Figure 5A). Simultaneous addition of LTB4 to upper and lower wells abrogated cell migration, confirming that our findings were indeed due to chemotaxis, not merely chemokinesis (Figure 5B). Pretreatment of SMCs with pertussis toxin also ablated LTB4-triggered chemotaxis, consistent with the involvement of a Gi-coupled signaling pathway (Figure 5A). The selective BLT1 antagonist CP-105,696 efficiently inhibited SMC migration, suggesting that BLT1 was the primary receptor mediating the observed effect (Figure 5A). This finding was then confirmed by chemotaxis assays with BLT1-deficient SMCs, which also had markedly diminished migration to LTB4 (Figure 5A). Although LTB4 was a potent agonist for SMC chemotaxis, it did not stimulate SMC proliferation (Figure 5C and 5D). At higher serum doses, there was neither a synergistic nor adverse effect on proliferation.
|
We next performed signaling studies to characterize pathways downstream of BLT1 in SMCs. FAK is a key modulator of cell-matrix interactions and cytoskeletal rearrangement leading to SMC migration.32 Exposure to LTB4 consistently increased FAK activation, as assessed by Western blotting with a phospho-specific antibody (Figure 6A). Further experiments evaluated the impact of LTB4 stimulation on the ERK 1/2 pathway, which is more closely tied to SMC proliferation33,34 (Figure 6B). Interestingly, this pathway was suppressed 1 hour after LTB4 stimulation, a finding consistent with the lack of response to LTB4 observed in the proliferation assays.
|
In light of our data demonstrating the expression and function of SMC BLT1 in vitro, we performed immunohistochemistry on human atherosclerotic plaques using a recently developed anti-human BLT1 Ab31 (Figure 7A through 7C). Our analysis revealed the expression of BLT1+ cells within atherosclerotic lesions, which was particularly notable in lipid-rich areas. Adjacent sections of the same atherosclerotic tissue stained for BLT1 showed colocalization with SMCs, particularly in the area of the fibrous cap. Macrophages within the lesion had even more robust BLT1 expression. Interestingly, in areas of neovascularization, we also saw evidence for BLT1 expression on CD31+ endothelial cells and apparently in the SMCs of the walls of the neovessels. The isotype-matched control antibody showed no signal.
|
|
Discussion |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
Emerging evidence has implicated the LTB4-BLT1 pathway in chronic inflammatory diseases, including atherosclerosis. Here we have shown that the absence of BLT1 confers a >2-fold decrease in early lesion formation as assessed by both aortic en face and cross-sectional analyses of plaque burden in apoE–/–/Blt1–/– mice compared with apoE–/– controls. Reduction in lesion formation was evident in all parts of the aorta and was similar in both male and female mice. Histochemical analysis revealed a remarkable reduction in SMCs in BLT1-deficient mice, which was confirmed by a reduction in SMC-specific
-actin message in the lesions. We report here novel evidence of the expression and function of BLT1 on SMCs in vitro and the presence of BLT1 on SMCs in atherosclerotic lesions in humans. Our study agrees with a report in which a small-molecule BLT1 antagonist reduced plaque burden in Ldlr–/– and apoE–/– mice,19 a finding that was confirmed more recently in apoE–/–/Blt1–/– compound-deficient mice.20 Both studies suggested that loss of BLT1-mediated macrophage activation accounted for the diminished atherogenesis. Results observed in the compound-deficient mice led investigators to study LTB4-triggered gene regulation in a rat basophilic cell line, which revealed increased levels of the scavenger receptor CD36 and the chemokine monocyte chemoattractant protein (MCP)-1. However, LTB4-triggered augmentation in CD36 and/or MCP-1 mRNA seen in the rat basophilic cell line cells could not be confirmed in primary macrophages or macrophage cell lines. Thus, the mechanisms by which BLT1 contributes to lesion formation have remained incompletely defined. Furthermore, the notion that BLT1 may function in the recruitment of other cellular plaque constituents has not been previously appreciated. Neither of the above reports specifically evaluated the effects of the LTB4-BLT1 pathway on the SMC component in atherosclerotic lesions.
The prevailing dogma is that chemoattractants contribute to atherosclerotic lesion development by chemokine-triggered leukocyte firm adhesion and chemotaxis into inflamed tissues. Although chemokines are best described for their role in host immunity, a growing body of evidence suggests a broader range of biological targets than was first appreciated. For example, mice deficient in the chemokine stromal derived factor-135 or its receptor CXCR436,37 have lethal defects of the cardiac intraventricular septum and aberrant migration of cerebellar neurons. In terms of vascular pathology, prior studies have implicated chemokine-dependent responses in SMCs. Roque et al38 evaluated the response to arterial injury in animals lacking the MCP-1 receptor CCR2. One month after the insult, CCR2-deficient mice had preserved leukocyte accumulation but a profound reduction in intimal lesion area, suggesting CCR2-dependent effects on SMC recruitment. More recent work has also demonstrated that SMCs within the neointima of atherosclerotic lesions express the fractalkine receptor CX3CR1 and that cultured vascular SMCs undergo chemotaxis to fractalkine that can be inhibited by G-protein inactivation with pertussis toxin.39 We therefore extend these prior observations by providing novel evidence for the induction of the lipid chemoattractant receptor BLT1 on SMCs. The present study, coupled with our recent findings demonstrating the marked induction of BLT1 in the cytokine-induced transition from naïve to effector T cells,14 suggests that BLT1 may have more widespread effects in inflammation than originally postulated.14 We hypothesize that there may be even more profound effects of BLT1 deletion in models in which SMCs dominate the response to injury such as after arterial wall mechanical injury.
Although murine strains such as apoE–/– mice have important features of atherosclerotic disease, they do not replicate the complex lesions seen in humans. Modulation of the LTB4-BLT1 pathway in humans might be more complex than previously suggested19 because of unanticipated effects on SMCs. In early atherosclerotic lesions, there is intense vessel wall remodeling involving the recruitment and proliferation of SMCs, which in turn contribute to extracellular matrix formation and overall plaque volume. In late-stage lesions in humans, however, SMCs form fibrous caps that are believed to inhibit plaque rupture. Thus, early intervention in the LTB4-BLT1 pathway might be most beneficial both to capture the more robust effects early in lesion development, as suggested by our study, and to avoid potential unintended effects on plaque stability of more mature lesions.
Our studies suggest a role for LTB4 in SMC migration but no effect on SMC proliferation. Concordant with the functional assays, signaling studies revealed activation of focal adhesion-associated kinase and inhibition of the proliferation-associated ERK 1/2 pathway. However, a thorough assessment of the functionally relevant pathways governing BLT1-dependent cell movement remains the focus of future investigation. Our studies, of course, do not preclude a role for BLT1 in proliferative processes requiring additional signals that might be present in the vessel wall.
The chemotactic response of SMCs to LTB4 resembled that of leukocytes.14 These findings agree with the markedly diminished lesional SMC accumulation observed in the apoE–/–/Blt1–/- mice. However, our studies do not preclude BLT1-dependent modulation of smooth muscle responses in the vessel wall through its effects on monocytes or T cells. The initial studies of MCP-1 and CCR2 deletion in proatherogenic strains did not specifically evaluate SMC content in the lesions.40,41 More recent work using anti-MCP-1 gene therapy diminished macrophage accumulation but actually increased lesional SMC content.42 Deletion of the fractalkine receptor, which mediates monocyte recruitment43 and potentially SMC responses,39 had no effect on SMC recruitment to atherosclerotic plaques.44 Thus, mediators of monocyte recruitment do not necessarily directly or indirectly modulate vessel wall SMC biology as well. Bone marrow transplantation studies between BLT1 knockout and wild-type mice are necessary to dissect primary leukocyte versus nonleukocyte contributions to lesion formation.
Multiple lines of investigation have implicated the LTB4-BLT1 axis in atherogenesis in both murine systems and humans. As with classic peptide chemokines, the pleiotropic effects of lipid chemoattractants in disease contexts are increasingly appreciated. Our new findings expand a role for BLT1 in regulating all major vessel wall constituents, thus underscoring its therapeutic promise for a variety of vascular diseases.
|
Acknowledgments |
|---|
We gratefully acknowledge support from the NIH to Drs Heller, Libby, Luster, and Gerszten. Drs Gerszten and Libby are supported by the Donald W. Reynolds Foundation. Human carotid plaque specimens were kindly provided by Dr Libby through the Cardiovascular Tissue Bank at Brigham and Women’s Hospital. We also acknowledge Karen Mendelsohn for assistance with immunohistochemistry.
|
References |
|---|
|
TopAbstractIntroductionMethodsResultsDiscussionReferences |
|---|
1. Tager AM, Dufour JH, Goodarzi K, Bercury SD, von Andrian UH, Luster AD. BLTR mediates leukotriene B(4)-induced chemotaxis and adhesion and plays a dominant role in eosinophil accumulation in a murine model of peritonitis. J Exp Med. 2000; 192: 439–446.
2. Goodarzi K, Goodarzi M, Tager AM, Luster AD, von Andrian UH. Leukotriene B4 and BLT1 control cytotoxic effector T cell recruitment to inflamed tissues. Nat Immunol. 2003; 4: 965–973.[CrossRef][Medline] [Order article via Infotrieve]
3. Ford-Hutchinson AW, Bray MA, Doig MV, Shipley ME, Smith MJ. Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear lymphocytes. Nature. 1980; 286: 264–265.[CrossRef][Medline] [Order article via Infotrieve]
4. Ford-Hutchinson AW. Leukotriene B4 in inflammation. Crit Rev Immunol. 1990; 10: 1–12.[Medline] [Order article via Infotrieve]
5. Ott VL, Cambier JC, Kappler J, Marrack P, Swanson BJ. Mast cell-dependent migration of effector CD8+ T cells through production of leukotriene B4. Nat Immunol. 2003; 4: 974–981.[CrossRef][Medline] [Order article via Infotrieve]
6. Samuelsson B. Leukotrienes: mediators of immediate hypersensitivity reactions and inflammation. Science. 1983; 220: 568–575.
7. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science. 2001; 294: 1871–1875.
8. Funk CD. 5-Lipoxygenase and leukotrienes. Am J Respir Crit Care Med. 2000; 161: s120–s124.[Medline] [Order article via Infotrieve]
9. Yokomizo T, Izumi T, Chang K, Takuwa Y, Shimizu T. A G-protein-coupled receptor for leukotriene B4 that mediates chemotaxis. Nature. 1997; 387: 620–624.[CrossRef][Medline] [Order article via Infotrieve]
10. Yokomizo T, Masuda K, Kato K, Toda A, Izumi T, Shimizu T. Leukotriene B4 receptor. Cloning and intracellular signaling. Am J Respir Crit Care Med. 2000; 161: S51–S55.
11. Izumi T. Leukotriene receptors: classification, gene expression, and signal transduction. J Biochem. 2002; 132: 1–6.
12. Yokomizo T, Kato K, Terawaki K, Izumi T, Shimizu T. A second leukotriene B(4) receptor, BLT2: a new therapeutic target in inflammation and immunological disorders. J Exp Med. 2000; 192: 421–432.
13. Tager AM, Luster AD. BLT1 and BLT2: the leukotriene B(4) receptors. Prostaglandins Leukot Essent Fatty Acids. 2003; 69: 123–134.[CrossRef][Medline] [Order article via Infotrieve]
14. Tager AM, Bromley SK, Medoff BD, Islam SA, Bercury SD, Friedrich EB, Carafone AD, Gerszten RE, Luster AD. Leukotriene B4 receptor BLT1 mediates early effector T cell recruitment. Nat Immunol. 2003; 4: 982–990.[CrossRef][Medline] [Order article via Infotrieve]
15. Spanbroek R, Grabner R, Lotzer K, Hildner M, Urbach A, Ruhling K, Moos MP, Kaiser B, Cohnert TU, Wahlers T, Zieske A, Plenz G, Robenek H, Salbach P, Kuhn H, Radmark O, Samuelsson B, Habenicht AJ. Expanding expression of the 5-lipoxygenase pathway within the arterial wall during human atherogenesis. Proc Natl Acad Sci U S A. 2003; 100: 1238–1243.
16. De Caterina R, Mazzone A, Giannessi D, Sicari R, Pelosi W, Lazzerini G, Azzara A, Forder R, Carey F, Caruso D, et al. Leukotriene B4 production in human atherosclerotic plaques. Biomed Biochim Acta. 1988; 47: S182–S185.[Medline] [Order article via Infotrieve]
17. Dwyer JH, Allayee H, Dwyer KM, Fan J, Wu H, Mar R, Lusis AJ, Mehrabian M. Arachidonate 5-lipoxygenase promoter genotype, dietary arachidonic acid, and atherosclerosis. N Engl J Med. 2004; 350: 29–37.
18. Helgadottir A, Manolescu A, Thorleifsson G, Gretarsdottir S, Jonsdottir H, Thorsteinsdottir U, Samani NJ, Gudmundsson G, Grant SF, Thorgeirsson G, Sveinbjornsdottir S, Valdimarsson EM, Matthiasson SE, Johannsson H, Gudmundsdottir O, Gurney ME, Sainz J, Thorhallsdottir M, Andresdottir M, Frigge ML, Topol EJ, Kong A, Gudnason V, Hakonarson H, Gulcher JR, Stefansson K. The gene encoding 5-lipoxygenase activating protein confers risk of myocardial infarction and stroke. Nat Genet. 2004; 36: 233–239.[CrossRef][Medline] [Order article via Infotrieve]
19. Aiello RJ, Bourassa PA, Lindsey S, Weng W, Freeman A, Showell HJ. Leukotriene B4 receptor antagonism reduces monocytic foam cells in mice. Arterioscler Thromb Vasc Biol. 2002; 22: 443–449.
20. Subbarao K, Jala VR, Mathis S, Suttles J, Zacharias W, Ahamed J, Ali H, Tseng MT, Haribabu B. Role of leukotriene B4 receptors in the development of atherosclerosis: potential mechanisms. Arterioscler Thromb Vasc Biol. 2004; 24: 369–375.
21. Plump AS, Smith JD, Hayek T, Aalto-Setala K, Walsh A, Verstuyft JG, Rubin EM, Breslow JL. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 1992; 71: 343–353.[CrossRef][Medline] [Order article via Infotrieve]
22. Kuhlencordt PJ, Chen J, Han F, Astern J, Huang PL. Genetic deficiency of inducible nitric oxide synthase reduces atherosclerosis and lowers plasma lipid peroxides in apolipoprotein E-knockout mice. Circulation. 2001; 103: 3099–3104.
23. Kuhlencordt PJ, Gyurko R, Han F, Scherrer-Crosbie M, Aretz TH, Hajjar R, Picard MH, Huang PL. Accelerated atherosclerosis, aortic aneurysm formation, and ischemic heart disease in apolipoprotein E/endothelial nitric oxide synthase double-knockout mice. Circulation. 2001; 104: 448–454.
24. Bjorkbacka H, Kunjathoor VV, Moore KJ, Koehn S, Ordija CM, Lee MA, Means T, Halmen K, Luster AD, Golenbock DT, Freeman MW. Reduced atherosclerosis in MyD88-null mice links elevated serum cholesterol levels to activation of innate immunity signaling pathways. Nat Med. 2004; 10: 416–421.[CrossRef][Medline] [Order article via Infotrieve]
25. Ray JL, Leach R, Herbert JM, Benson M. Isolation of vascular smooth muscle cells from a single murine aorta. Methods Cell Sci. 2001; 23: 185–188.[CrossRef][Medline] [Order article via Infotrieve]
26. Means TK, Hayashi F, Smith KD, Aderem A, Luster AD. The Toll-like receptor 5 stimulus bacterial flagellin induces maturation and chemokine production in human dendritic cells. J Immunol. 2003; 170: 5165–5175.
27. Friedrich EB, Sinha S, Li L, Dedhar S, Force T, Rosenzweig A, Gerszten RE. Role of integrin-linked kinase in leukocyte recruitment. J Biol Chem. 2002; 277: 16371–16375.
28. Matsui T, Li L, del Monte F, Fukui Y, Franke TF, Hajjar RJ, Rosenzweig A. Adenoviral gene transfer of activated phosphatidylinositol 3'-kinase and Akt inhibits apoptosis of hypoxic cardiomyocytes in vitro. Circulation. 1999; 100: 2373–2379.
29. Jones LJ, Gray M, Yue ST, Haugland RP, Singer VL. Sensitive determination of cell number using the CyQUANT cell proliferation assay. J Immunol Methods. 2001; 254: 85–98.[CrossRef][Medline] [Order article via Infotrieve]
30. Friedrich EB, Liu E, Sinha S, Cook S, Milstone DS, MacRae CA, Mariotti M, Kuhlencordt PJ, Force T, Rosenzweig A, St Arnaud R, Dedhar S, Gerszten RE. Integrin-linked kinase regulates endothelial cell survival and vascular development. Mol Cell Biol. 2004; 24: 8134–8144.
31. Pettersson A, Boketoft A, Sabirsh A, Nilsson NE, Kotarsky K, Olde B, Owman C. First-generation monoclonal antibodies identifying the human leukotriene B(4) receptor-1. Biochem Biophys Res Commun. 2000; 279: 520–525.[CrossRef][Medline] [Order article via Infotrieve]
32. Carragher NO, Levkau B, Ross R, Raines EW. Degraded collagen fragments promote rapid disassembly of smooth muscle focal adhesions that correlates with cleavage of pp125(FAK), paxillin, and talin. J Cell Biol. 1999; 147: 619–630.
33. Calabro P, Samudio I, Willerson JT, Yeh ET. Resistin promotes smooth muscle cell proliferation through activation of extracellular signal-regulated kinase 1/2 and phosphatidylinositol 3-kinase pathways. Circulation. 2004; 110: 3335–3340.
34. Hu Y, Cheng L, Hochleitner BW, Xu Q. Activation of mitogen-activated protein kinases (ERK/JNK) and AP-1 transcription factor in rat carotid arteries after balloon injury. Arterioscler Thromb Vasc Biol. 1997; 17: 2808–2816.
35. Nagasawa T, Hirota S, Tachibana K, Takakura N, Nishikawa S, Kitamura Y, Yoshida N, Kikutani H, Kishimoto T. Defects of B-cell lymphopoiesis and bone-marrow myelopoiesis in mice lacking the CXC chemokine PBSF/SDF-1. Nature. 1996; 382: 635–638.[CrossRef][Medline] [Order article via Infotrieve]
36. Tachibana K, Hirota S, Iizasa H, Yoshida H, Kawabata K, Kataoka Y, Kitamura Y, Matsushima K, Yoshida N, Nishikawa S, Kishimoto T, Nagasawa T. The chemokine receptor CXCR4 is essential for vascularization of the gastrointestinal tract. Nature. 1998; 393: 591–594.[CrossRef][Medline] [Order article via Infotrieve]
37. Zou YR, Kottmann AH, Kuroda M, Taniuchi I, Littman DR. Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development. Nature. 1998; 393: 595–599.[CrossRef][Medline] [Order article via Infotrieve]
38. Roque M, Kim WJ, Gazdoin M, Malik A, Reis ED, Fallon JT, Badimon JJ, Charo IF, Taubman MB. CCR2 deficiency decreases intimal hyperplasia after arterial injury. Arterioscler Thromb Vasc Biol. 2002; 22: 554–559.
39. Lucas AD, Bursill C, Guzik TJ, Sadowski J, Channon KM, Greaves DR. Smooth muscle cells in human atherosclerotic plaques express the fractalkine receptor CX3CR1 and undergo chemotaxis to the CX3C chemokine fractalkine (CX3CL1). Circulation. 2003; 108: 2498–2504.
40. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell. 1998; 2: 275–281.[CrossRef][Medline] [Order article via Infotrieve]
41. Boring L, Gosling J, Cleary M, Charo I. Decreased lesion formation in CCR2–/– mice reveals a role for chemokines in the initiation of atherosclerosis. Nature. 1998; 394: 894–897.[CrossRef][Medline] [Order article via Infotrieve]
42. Inoue S, Egashira K, Ni W, Kitamoto S, Usui M, Otani K, Ishibashi M, Hiasa K, Nishida K, Takeshita A. Anti-monocyte chemoattractant protein-1 gene therapy limits progression and destabilization of established atherosclerosis in apolipoprotein E-knockout mice. Circulation. 2002; 106: 2700–2706.
43. Haskell CA, Cleary MD, Charo IF. Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction: rapid flow arrest of CX3CR1-expressing cells is independent of G-protein activation. J Biol Chem. 1999; 274: 10053–10058.
44. Combadiere C, Potteaux S, Gao JL, Esposito B, Casanova S, Lee EJ, Debre P, Tedgui A, Murphy PM, Mallat Z. Decreased atherosclerotic lesion formation in CX3CR1/apolipoprotein E double knockout mice. Circulation. 2003; 107: 1009–1016.
 |
|
 |
|
  M. C. Barth, N. Ahluwalia, T. J. T. Anderson, G. J. Hardy, S. Sinha, J. A. Alvarez-Cardona, I. E. Pruitt, E. P. Rhee, R. A. Colvin, and R. E. Gerszten Kynurenic Acid Triggers Firm Arrest of Leukocytes to Vascular Endothelium under Flow Conditions J. Biol. Chem., July 17, 2009; 284(29): 19189 - 19195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Miyahara, H. Ohnishi, S. Miyahara, K. Takeda, S. Matsubara, H. Matsuda, M. Okamoto, J. E. Loader, A. Joetham, M. Tanimoto, et al. Leukotriene B4 Release from Mast Cells in IgE-Mediated Airway Hyperresponsiveness and Inflammation Am. J. Respir. Cell Mol. Biol., June 1, 2009; 40(6): 672 - 682. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Hlawaty, M.-P. Jacob, L. Louedec, D. Letourneur, C. Brink, J.-B. Michel, L. Feldman, and M. Back Leukotriene Receptor Antagonism and the Prevention of Extracellular Matrix Degradation During Atherosclerosis and In-Stent Stenosis Arterioscler. Thromb. Vasc. Biol., April 1, 2009; 29(4): 518 - 524. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. L. King, A. Y. Lin, F. Kristo, T. J.T. Anderson, N. Ahluwalia, G. J. Hardy, A. P. Owens III, D. A. Howatt, D. Shen, A. M. Tager, et al. Interferon-{gamma} and the Interferon-Inducible Chemokine CXCL10 Protect Against Aneurysm Formation and Rupture Circulation, January 27, 2009; 119(3): 426 - 435. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Allayee, A. Baylin, J. Hartiala, H. Wijesuriya, M. Mehrabian, A. J Lusis, and H. Campos Nutrigenetic association of the 5-lipoxygenase gene with myocardial infarction Am. J. Clinical Nutrition, October 1, 2008; 88(4): 934 - 940. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Kaetsu, Y. Yamamoto, S. Sugihara, T. Matsuura, G. Igawa, K. Matsubara, O. Igawa, C. Shigemasa, and I. Hisatome Role of cysteinyl leukotrienes in the proliferation and the migration of murine vascular smooth muscle cells in vivo and in vitro Cardiovasc Res, October 1, 2007; 76(1): 160 - 166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Ahluwalia, A. Y. Lin, A. M. Tager, I. E. Pruitt, T. J. T. Anderson, F. Kristo, D. Shen, A. R. Cruz, M. Aikawa, A. D. Luster, et al. Inhibited Aortic Aneurysm Formation in BLT1-Deficient Mice J. Immunol., July 1, 2007; 179(1): 691 - 697. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. K. Hansson Epidemiology Complements Immunology in the Heart Arterioscler. Thromb. Vasc. Biol., October 1, 2006; 26(10): 2178 - 2180. [Full Text] [PDF]
|
|
|
|
|
|
C. D. Funk Lipoxygenase Pathways as Mediators of Early Inflammatory Events in Atherosclerosis. Arterioscler. Thromb. Vasc. Biol., June 1, 2006; 26(6): 1204 - 1206. [Full Text] [PDF]
|
|
|
|
 |
|
 H. Qiu, A. Gabrielsen, H. E. Agardh, M. Wan, A. Wetterholm, C.-H. Wong, U. Hedin, J. Swedenborg, G. K. Hansson, B. Samuelsson, et al. Expression of 5-lipoxygenase and leukotriene A4 hydrolase in human atherosclerotic lesions correlates with symptoms of plaque instability PNAS, May 23, 2006; 103(21): 8161 - 8166. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. A. Heller, E. Liu, A. M. Tager, Q. Yuan, A. Y. Lin, N. Ahluwalia, K. Jones, S. L. Koehn, V. M. Lok, E. Aikawa, et al. Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells Circulation, May 16, 2006; 113(19): 2301 - 2312. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Tedgui and Z. Mallat Cytokines in Atherosclerosis: Pathogenic and Regulatory Pathways Physiol Rev, April 1, 2006; 86(2): 515 - 581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Back, D.-x. Bu, R. Branstrom, Y. Sheikine, Z.-Q. Yan, and G. K. Hansson Leukotriene B4 signaling through NF-{kappa}B-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia PNAS, November 29, 2005; 102(48): 17501 - 17506. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||